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Graft-versus-host disease (GVHD), as well as
graft-versus-leukemia effect (GVL), are essentially
allo-immune reactions, which are induced by the en-
grafted donor T cells that recognize the host-derived
allo-antigens presented on their targets (Figure 1). In
HLA-matched transplantation, these antigens are
called minor histocompatibility antigens (mHags),
and are typically defined by the host single nucleotide
polymorphisms (SNPs) that are not shared by the
donor and therefore considered to be genetically
mismatched between the donor and the recipient
[1–3]. Thus, the development of both allo-reactions
absolutely depends on the presence of 1 or more
mismatched mHags, although these reactions could
be further modified by other genetic as well as environ-
mental factors, including, cytokine polymorphisms
and GVHD prophylaxis. So, in view of better prevent-
ing GVHD and specifically targeting allo-immunity to
the tumor component, central questions are what
mHAgs are responsible for the development of
GVHDorGVL and what genetic factors can influence
the overall reactions, which are the plausible targets of
genome-wide association studies (GWAS) [4-8].
To identify the genetic basis of GVHD, we con-
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6/j.bbmt.2008.11.020SNPs using Affymetrix GeneChip platforms [9,10] in
donors and recipients from 1,598 unrelated transplants
performed through the JapanMarrowDonor Program
(JMDP). All transplants were matched for HLA-A, B,
C, DRB1, and DQB1 by high-resolution DNA typing,
while 1033 (63%) transplants were mismatched for
HLA-DPB1. Six hundred fifty-six (41.7%) and 245
(14.9%) of transplants had developed grade II-IV
and grade III-IV of acute GVHD (aGVHD), respec-
tively. Overall SNP call rates exceeded 98% both in
donors and in recipients. Unobserved HapMap
PhaseII SNPs were rigorously imputed from the gen-
otyped SNPs [11-13]. After excluding those disquali-
fied SNPs showing \95% call rate, deviation from
Hardy-Weinberg equilibrium, or \5% minor allele
frequency, 1,276,699 SNPs were tested for association
with development of aGVHD and chronic GVHD
(cGVHD), relapse, and overall survival (OS), by calcu-
lating log-rank statistics for each SNP. Statistical
thresholds for genome-wide P value of .05 were deter-
mined empirically by doing 1,000 permutations for
each analysis. Association tests were performed with
regard to the simple genotype of donor and recipient
SNPs. Alternatively, to identify possible mHag loci,
GWAS were performed based on the allele-mismatch
defined for each SNP locus, rather than simple SNP
genotypes in donors and recipients. In the latter
setting, associations were tested within the subgroups
that shared particular HLA-types based on HLA-
restriction. Generally speaking, the sample size of
1,600 transplants in the current study was relatively
small compared to the size of typical GWAS studies,
and it was further reduced in the subgroup analysis
[8]. Thus, it was likely that we could find only those
mHag loci that were restricted to major HLA alleles
and whose allele-mismatch conferred strong genetic
effects on the development of GvHD [14,15]. How-
ever, this did not necessarily preclude conducting the
current study, because it was such mHags that are
thought to be clinically relevant.39
Figure 1. Allo-immunity plays central roles in HSCT.
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aGVHD under the assumption of no HLA restriction,
SNPs around the HLA-DPB1 locus showed strong
association with the development of grade II-IV
aGVHD with the maximum P value of 1.81  1029
at rs6937034, and thus, the GWAS successfully
captured the association of HLA-DPB1 allele mis-
match as directly defined by high-resolutionDNA typ-
ing (hazard ratio [HR] 5 1.91, P 5 2.88  10213)
(Figure 2) [16]. No other loci were identified that
were significantly associated with aGVHD under the
assumption of no HLA restrictions. To identify the
target mHags for aGVHD, we further performed sub-Figure 2. Representative results of GWAS based on genotype mismatch.2lo
ciation tests for genotype mismatch under no HLA restriction (A), and undergroup analyses, in which the analysis were confined to
those transplants sharing major HLA types among the
Japanese population [17]. Six loci were identified as
candidate mHag loci. rs17473423 on chr12 was associ-
ated with the A*2402/B*5201/Cw*1201/DRB1*1501/
DQB1*0601, which represents the most prevalent
HLA haplotype among the Japanese population and
shared in 40% of unrelated transplants in Japanese
(grade III-IV aGVHD, with maximum P 5 3.99 
10213) (Figures 2b and 3b). rs9657655 on chr9 was as-
sociated with another common haplotype in Japanese,
A*3303/B*4403/Cw*1403 (grade III-IV aGVHD with
maximum P 5 8.56  10210) (Figures 2c and 3b). We
found additional 4 loci that were associated with
DQB1*0501, Cw*0102, B*5201, and Cw*1202. We
also tested the association of GVHD with simple
genotype in either recipients or donors, though which
2 recipient SNPs were found to be associated with
aGVHD, rs5998746 on chr22 (P 5 3.41  1028) and
rs11873016 on chr18 (P 5 1.26  1028), whereas no
donor SNPs showed significant associations. Simi-
larly, we identified 4 candidate SNPs associated with
the development of severe cGVHD or relapse.
Our study provided a unique opportunity, in that
a combination of 2 different genotypes, rather than
mere genotypes in single individuals, is explored for as-
sociation with particular disease phenotypes through
whole genome association scanning. Although further
replication studies and biologic confirmation areg10P values are plotted in genetic order. Results are presented for asso-
the restriction to HLA DQB1*0601 (B) and HLA B*4403 (C).
Figure 3. QQ-plots of the statistics. QQ-plots of the analysis of genotype mismatch under no restriction on HLA (A), and restriction to HLA
DQB1*0601 (B) and HLA B*4403 (C) where observed test statistics values are plotted against expected values from 1000 random permutations
(red); 95% confidence intervals are also provided by shadows. Only the plots for the top 20,000 results are presented. The QQ-plots excluding the
SNPs that belong to the positive peak are also depicted in blue.
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ation studies of allo-SCT could provide a novel clue to
our understanding of the genetic basis of GVHD.ACKNOWLEDGMENTS
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